The National University of Singapore, Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, and National University Hospital, have established Singapore’s first integrated translational R&D hub that leverages on biochemical innovation and research data analytics to develop new methods of translating clinical research into clinical diagnostics.
The NUS-Agilent Hub for Translation & Capture (NUS-Agilent Hub comprises laboratories located in NUS and NUH, provides 1,000 square metres of research space to facilitate multidisciplinary collaborations among scientists, clinicians and industry partners to translate biochemical research into clinical applications. Through research in areas such as lipidomics and synthetic biology, and supported by data analytics, NUS and Agilent hope to develop innovative ways that enhance the accuracy of clinical diagnostics based on data obtained from patients’ blood samples. The initial research focus areas are cardiovascular disease and diabetes, which account for 30 per cent of all deaths in Singapore in 2017, and affected 440,000 Singaporean adults in 2014 respectively.
The NUS-Agilent Hub aims to be a global premier one-stop research centre for informing clinical testing through the use of emerging technologies and translational studies to provide greater insight and accuracy to clinical biochemistry testing. This collaboration between NUS, Agilent and NUH represents a unique and innovative approach to conducting joint research into important health issues and medical science. The “hub and satellite model” allows research to be conducted centrally, Singapore-based, but shared broadly, both locally, regionally as well as globally through key partnerships and alliances supported by NUS and Agilent.